Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit
This article was originally published in The Tan Sheet
Executive Summary
Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court
You may also be interested in...
Prilosec OTC Patent Extension Submission Pending At PTO
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
Mylan Says OTC, Rx Prilosec Not Bioequivalent In Study
Prilosec OTC is not bioequivalent to prescription Prilosec under the conditions of a small clinical study recently submitted to FDA by Mylan Labs, according to the firm
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication